— Know what they know.
Not Investment Advice
Also trades as: MYX.AX (ASX) · $vol 1M

MAYNF OTC

Mayne Pharma Group Limited
1W: -9.9% 1M: -14.9% 3M: +21.2% YTD: -3.4% 1Y: -41.2% 3Y: -15.6% 5Y: +676.7%
$2.00
+0.00 (+0.00%)
 
OTC · Healthcare · Medical - Pharmaceuticals · Tech Score Sell · Power 37 · $162.5M mcap · 69M float · 0.0051% daily turnover · Short 74% of daily vol
Smart Money Score
No convergence signal
Key Statistics
Market Cap$162.5M
52W Range1.4-4
Volume1,200
Avg Volume3,529
Beta1.00
Dividend—
Analyst Ratings
No analyst coverage
Company Info
CEOAaron Gray
Employees450
SectorHealthcare
IndustryMedical - Pharmaceuticals
IPO Date2013-03-22
1538 Main North Road
Salisbury South, SA 5106
AU
61 8 8209 2666
About Mayne Pharma Group Limited

Mayne Pharma Group Limited is an Australian-headquartered specialty pharmaceutical enterprise, engaged in the development, production, and marketing of both patented (branded) and generic drug formulations. Its commercial reach spans Australia, New Zealand, North America (covering the United States and Canada), Europe, and Asia. The company's operations are divided into four main segments: Metrics Contract Services, International, Branded Products, and Portfolio Products. Beyond its own product lines, Mayne Pharma offers sophisticated oral drug delivery technologies and comprehensive contract services—including pharmaceutical development, manufacturing, and analytical testing—to other businesses. Its strategic focus areas for specialty product distribution include dermatology, women's health, and infectious disease treatments. Originally established in 2005, the company operated under the name Halcygen Pharmaceuticals Limited before rebranding to Mayne Pharma Group Limited in November 2010. Its principal office is located in Salisbury South, Australia.

Recent Insider Trades

No insider trades found

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms